Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-18
    E.g., 2018-11-18

Articles

52102 items
12:00 AM, Nov 02, 2000  |  BC Extra | Financial News

Thursday market watch

The BioCentury 100 soared 4.4 percent on Thursday, beating out a 2.9 percent gain posted by the NASDAQ. Drug discovery company Pharmacopeia (PCOP) paved the way, closing up $8.75 (44 percent) to $28.50 after announcing...
12:00 AM, Nov 02, 2000  |  BC Extra | Financial News

Cima raises $147.5 million

Drug delivery company CIMA raised $147.5 million through the sale of 2.95 million shares at $50 in a follow-on underwritten by Deutsche Banc; SG Cowen; and Fahnestock. CIMA and selling stockholders will offer 442,500 shares...
12:00 AM, Nov 02, 2000  |  BC Extra | Financial News

Microbia raises $23 million

Antimicrobial drug company Microbia ( Cambridge, Mass.) raised $23 million in a venture financing. Investors included BancBoston Ventures; Essex Investment Management; Venrock Associates; Polaris Venture Partners; Aberdare Ventures; and other private investors....
12:00 AM, Nov 02, 2000  |  BC Extra | Clinical News

SuperGen up on Phase I/II decitabine data

SUPG was up $4.063 (31 percent) to $17 on Thursday after publishing in Blood data from an 8-patient U.S. Phase I/II trial showing that its decitabine chemotherapeutic modulator of DNA methylation was well tolerated...
12:00 AM, Nov 02, 2000  |  BC Extra | Clinical News

Amylin starts Phase II diabetes study

AMLN began placebo-controlled Phase II testing of its AC2993 synthetic exendin-4 in more than 100 patients with Type II diabetes who are not achieving adequate blood glucose target levels with their oral therapies. The study...
12:00 AM, Nov 02, 2000  |  BC Extra | Company News

Genomica licenses software to AVE

GNOM licensed its Discovery Manager genomics software to Aventis Pharma, the prescription drug business of Aventis (AVE). AVE will use the software to examine unknown expressed sequence tags and convert them into full length cDNAs....
12:00 AM, Nov 02, 2000  |  BC Extra | Company News

Aclara in microfluidics deal with Zeptosens

ACLA licensed a microfluidics patent application from Zeptosens (Witterswil, Switzerland) covering the use of microfluidic networks in which fluid movement is controlled via electricity. ACLA said the April 1993 filing date of the pending patent...
12:00 AM, Nov 02, 2000  |  BC Extra | Company News

Aurora and Senomyx enter taste/olfaction research deal

ABSC granted Senomyx (La Jolla, Calif.) exclusive rights to its functional genomics technology, including its green fluorescent protein (GFP) and beta-lactamase reporter technologies, for use with Senomyx's chemosensory gene targets to discover consumer products enhancing...
12:00 AM, Nov 02, 2000  |  BC Extra | Company News

KS Biomedix licenses antibodies to York Medical

York Medical received a license to co-develop KH-6H9Chi, an antibody to treat colon cancer from KS Biomedix (LSE:KSB). York will have the right to commercialize the product in the Americas, while KSB retains rights to...
12:00 AM, Nov 02, 2000  |  BC Extra | Company News

Admetric enters ADMET deal with SmithKline

Admetric BioChem ( Cambridge, Mass.) signed a second agreement with SmithKline Beecham (SBH; LSE:SB) to develop and evaluate Admetric's technology for profiling absorption, distribution, metabolism, excretion, and toxicology (ADMET) properties of drug candidates. Admetric will...

Pages